CIK 0001855175
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 271467257
- Phone
- +1 858-333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,142
- in 1 filing, $41K under 10b5-1 plans
Net −$41,142. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-31 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2024-08-13 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Exercise or conversion | +12,800 | $1.01 | $13K | 12,800 |
| 2024-08-13 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Exercise or conversion · Stock Option (right to buy) | −12,800 | 161,394 | ||
| 2024-05-24 | Huhn Stephen L. CMO & Sr VP, Clinical Dev. | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 |
Page 1 of 1 · 4 trades